Takeda is launching a restructuring, targeting nearly $1.3 billion in annual savings. Generic versions of Novo Nordisk's ...
There’s no need to dive fast and furious into every single wellness trend, according to a Ludacris-fronted campaign from Bayer’s consumer health division. | There’s no need to dive fast and furious ...
With an end-of-week green light from the FDA, Rocket Pharmaceuticals has officially broken into commercial orbit. | Rocket ...
While Lilly’s position in the obesity market and wider GLP-1 space has remained largely unshakeable in recent months, a | ...
Addressing pressing questions about upcoming ATTR-CM competition and market opportunity, Alnylam management on Tuesday ...
After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another ...
Roche’s Genentech is backing this year’s Walk to End Lupus Now, taking up a sponsorship opportunity claimed by GSK in ...
Ionis Pharmaceuticals is dramatically lowering the price of its blockbuster hopeful Tryngolza (olezarsen) as it prepares to ...
Large pharmaceutical companies, each with at least $20 billion in 2025 revenue, collectively reduced their workforces by more ...
Amid an outpouring of pharma investment dollars into China, Novartis is the latest multinational drugmaker lining up to ...
With key expansions coming to fruition on either side of the pond, specialist CDMO Hovione is making sure that drugmakers can ...
Gilead increased CEO Daniel O’Day's compensation by 20% in 2025 to $28.4 million, putting him among the highest-paid chief ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results